{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ivacaftor+150+MG&page=2", "query": { "intervention": "Ivacaftor 150 MG", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 56, "total_pages": 6, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ivacaftor+150+MG&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ivacaftor+150+MG&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-04T23:40:20.376Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00909532", "title": "Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older With the G551D Mutation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "Ivacaftor", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 167, "start_date": "2009-06", "completion_date": "2012-11", "has_results": true, "last_update_posted_date": "2013-01-18", "last_synced_at": "2026-10-04T23:40:20.376Z", "location_count": 39, "location_summary": "Birmingham, Alabama • Oakland, California • Palo Alto, California + 34 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Oakland", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00909532" }, { "nct_id": "NCT00457821", "title": "Safety Study of Ivacaftor in Subjects With Cystic Fibrosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "Ivacaftor 25 mg/75 mg", "type": "DRUG" }, { "name": "Ivacaftor 75 mg/150 mg", "type": "DRUG" }, { "name": "Ivacaftor 150 mg or 250 mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 39, "start_date": "2007-05", "completion_date": "2008-08", "has_results": true, "last_update_posted_date": "2012-10-05", "last_synced_at": "2026-10-04T23:40:20.376Z", "location_count": 13, "location_summary": "Birmingham, Alabama • Palo Alto, California • Aurora, Colorado + 9 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Palo Alto", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00457821" }, { "nct_id": "NCT01614457", "title": "Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have the R117H-CF Transmembrane Conductance Regulator (CFTR) Mutation (KONDUCT)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "Ivacaftor", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": null, "sex": "ALL", "summary": "6 Years and older" }, "enrollment_count": 70, "start_date": "2012-07", "completion_date": "2013-10", "has_results": true, "last_update_posted_date": "2015-02-12", "last_synced_at": "2026-10-04T23:40:20.376Z", "location_count": 29, "location_summary": "Birmingham, Alabama • Palo Alto, California • Hartford, Connecticut + 26 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Palo Alto", "state": "California" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01614457" }, { "nct_id": "NCT01225211", "title": "Study of VX-809 Alone and in Combination With VX-770 in Cystic Fibrosis (CF) Patients Homozygous or Heterozygous for the F508del-CFTR Mutation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "Lumacaftor", "type": "DRUG" }, { "name": "Ivacaftor", "type": "DRUG" }, { "name": "Lumacaftor Placebo", "type": "DRUG" }, { "name": "Ivacaftor Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 312, "start_date": "2010-10", "completion_date": "2014-04", "has_results": true, "last_update_posted_date": "2015-10-05", "last_synced_at": "2026-10-04T23:40:20.376Z", "location_count": 38, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • La Jolla, California + 35 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "La Jolla", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01225211" }, { "nct_id": "NCT02412111", "title": "A Phase 3 Study of Tezacaftor (VX-661) in Combination With Ivacaftor (VX-770) in Subjects Aged 12 Years and Older With Cystic Fibrosis (CF), Who Have One F508del-CFTR Mutation and a Second Mutation That Has Been Demonstrated to be Clinically Responsive to Ivacaftor", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "Ivacaftor", "type": "DRUG" }, { "name": "Tezacaftor/Ivacaftor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 156, "start_date": "2015-06", "completion_date": "2017-09", "has_results": true, "last_update_posted_date": "2019-01-08", "last_synced_at": "2026-10-04T23:40:20.376Z", "location_count": 33, "location_summary": "Birmingham, Alabama • Oakland, California • San Diego, California + 30 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Oakland", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02412111" }, { "nct_id": "NCT02516410", "title": "A Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "VX-661 plus ivacaftor combination", "type": "DRUG" }, { "name": "Ivacaftor", "type": "DRUG" }, { "name": "Placebo (matched to VX-661 plus ivacaftor combination)", "type": "DRUG" }, { "name": "Placebo (matched to ivacaftor)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 168, "start_date": "2015-08", "completion_date": "2016-06-07", "has_results": true, "last_update_posted_date": "2018-06-12", "last_synced_at": "2026-10-04T23:40:20.376Z", "location_count": 22, "location_summary": "Birmingham, Alabama • La Jolla, California • Los Angeles, California + 19 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02516410" }, { "nct_id": "NCT01161537", "title": "Study of the Effect of VX-770 on Hyperpolarized Helium-3 Magnetic Resonance Imaging in Subjects With Cystic Fibrosis and the G551D Mutation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "VX-770", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 13, "start_date": "2010-10", "completion_date": "2013-02", "has_results": true, "last_update_posted_date": "2014-07-31", "last_synced_at": "2026-10-04T23:40:20.376Z", "location_count": 1, "location_summary": "Charlottesville, Virginia", "locations": [ { "city": "Charlottesville", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01161537" }, { "nct_id": "NCT01262352", "title": "Study of the Effect of Ivacaftor on Lung Clearance Index in Subjects With Cystic Fibrosis and the G551D Mutation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "Ivacaftor", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": null, "sex": "ALL", "summary": "6 Years and older" }, "enrollment_count": 21, "start_date": "2011-01", "completion_date": "2011-11", "has_results": true, "last_update_posted_date": "2013-02-11", "last_synced_at": "2026-10-04T23:40:20.376Z", "location_count": 4, "location_summary": "Stanford, California • Iowa City, Iowa • Durham, North Carolina + 1 more", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01262352" }, { "nct_id": "NCT03537651", "title": "A Study to Evaluate the Safety and Efficacy of Long-term Treatment With TEZ/IVA in CF Participants With an F508del CFTR Mutation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "TEZ/IVA", "type": "DRUG" }, { "name": "IVA", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": null, "sex": "ALL", "summary": "6 Years and older" }, "enrollment_count": 130, "start_date": "2018-04-25", "completion_date": "2023-09-29", "has_results": true, "last_update_posted_date": "2024-04-19", "last_synced_at": "2026-10-04T23:40:20.376Z", "location_count": 28, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Little Rock, Arkansas + 25 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT03537651" }, { "nct_id": "NCT07022327", "title": "Ivacaftor Impact in an Adolescent Without a Cystic Fibrosis-Associated CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) Mutation for Chronic Pancreatitis: Single-Patient Study Tracking Flare Frequency and Health Data Compared to Historical Records.", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Chronic Pancreatitis" ], "interventions": [ { "name": "Ivacaftor 150 MG (milligrams)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mission: Cure", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 1, "start_date": "2025-05-06", "completion_date": "2026-08", "has_results": false, "last_update_posted_date": "2025-06-15", "last_synced_at": "2026-10-04T23:40:20.376Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT07022327" } ] }